These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 8757422

  • 1. A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
    Vella S, Floridia M, Dally LG, Tomino C, Fragola V, Weimer LE, Milazzo F, Mazzotta F, Moroni M, Pastore G, Scalise G, Sinicco A, Ortona L, De Rienzo B, Dianzani F.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug 15; 12(5):462-9. PubMed ID: 8757422
    [Abstract] [Full Text] [Related]

  • 2. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
    Gatell JM, González-Lahoz J, Clotet B, Antunes F, Kasparova L, Gil-Aguado A, Saballs P, Santamaria JM, Podzamczer D, Miro JM, Jou A, Verdejo J, Doroana M, Thomis J.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul 15; 12(3):249-58. PubMed ID: 8673528
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
    Floridia M, Vella S, Seeber AC, Tomino C, Fragola V, Weimer LE, Ricciardulli D, Milazzo F, Gritti FM, Mazzotta F, Ranieri S, Chiodo F, Moroni M, Cargnel A, Bassetti D, Giannini V, Cremoni L, Concia E, Sinicco A, Carosi G, Alberici F, Dianzani F.
    J Infect Dis; 1997 Feb 15; 175(2):255-64. PubMed ID: 9203645
    [Abstract] [Full Text] [Related]

  • 4. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
    Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A.
    Cochrane Database Syst Rev; 2000 Feb 15; (3):CD002038. PubMed ID: 10908523
    [Abstract] [Full Text] [Related]

  • 5. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
    Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A.
    Cochrane Database Syst Rev; 2000 Feb 15; 2000(2):CD002038. PubMed ID: 10796851
    [Abstract] [Full Text] [Related]

  • 6. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
    Dolin R, Amato DA, Fischl MA, Pettinelli C, Beltangady M, Liou SH, Brown MJ, Cross AP, Hirsch MS, Hardy WD.
    Arch Intern Med; 1995 May 08; 155(9):961-74. PubMed ID: 7726705
    [Abstract] [Full Text] [Related]

  • 7. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
    Jablonowski H, Arasteh K, Staszewski S, Ruf B, Stellbrink HJ, Schrappe M, Stoehr A, Haase W, Schomaker U, von Eisenhart Rothe B.
    AIDS; 1995 May 08; 9(5):463-9. PubMed ID: 7639971
    [Abstract] [Full Text] [Related]

  • 8. Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
    d'Arminio Monforte A, Musicco M, Galli M, Paga C, La Regina A, Lazzarin A, Angarano G, Milazzo F, Gritti F, Arlotti M, Mazzotta F, Visco G, Aiuti F, Moroni M.
    Eur J Clin Microbiol Infect Dis; 1997 Feb 08; 16(2):135-42. PubMed ID: 9105840
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ, Allan JD, Fitch H, Jackson-Pope L, McLaren C, Canetta R, Groopman JE.
    Am J Med; 1991 Nov 08; 91(5):471-8. PubMed ID: 1659189
    [Abstract] [Full Text] [Related]

  • 10. ACTG 175 and Delta.
    Torres G.
    GMHC Treat Issues; 1995 Oct 08; 9(10):2-3. PubMed ID: 11362915
    [Abstract] [Full Text] [Related]

  • 11. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
    Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC.
    N Engl J Med; 1996 Oct 10; 335(15):1081-90. PubMed ID: 8813038
    [Abstract] [Full Text] [Related]

  • 12. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
    Lancet; 1996 Aug 03; 348(9023):283-91. PubMed ID: 8709686
    [Abstract] [Full Text] [Related]

  • 13. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug 03; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [Abstract] [Full Text] [Related]

  • 14. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
    Moyle GJ, Nelson MR, Hawkins D, Gazzard BG.
    Q J Med; 1993 Mar 03; 86(3):155-63. PubMed ID: 8387218
    [Abstract] [Full Text] [Related]

  • 15. Studies confirm value of early and combination treatments.
    Vazquez E.
    Posit Aware; 1995 Mar 03; VI(6):8. PubMed ID: 11363148
    [Abstract] [Full Text] [Related]

  • 16. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC, Martin ES.
    Ann Pharmacother; 1992 Nov 03; 26(11):1347-51. PubMed ID: 1362093
    [Abstract] [Full Text] [Related]

  • 17. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
    Whitfield RM, Bechtel LM, Starich GH.
    Alcohol Clin Exp Res; 1997 Feb 03; 21(1):122-7. PubMed ID: 9046384
    [Abstract] [Full Text] [Related]

  • 18. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M, Abrams D.
    N Engl J Med; 1996 Oct 10; 335(15):1099-106. PubMed ID: 8813040
    [Abstract] [Full Text] [Related]

  • 19. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
    Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Remick SC, Thompson M, MacArthur RD, Morey GE, Ramirez-Ronda CH, Bernstein BM, Sweet DE, Crane L, Peterson EA, Pachucki CT, Green SL, Brand J, Rios A, Dunkle LM, Cross A, Brown MJ, Ingraham P, Gugliotti R, Schindzielorz AH, Smaldone L.
    Ann Intern Med; 1994 Mar 01; 120(5):360-8. PubMed ID: 7905722
    [Abstract] [Full Text] [Related]

  • 20. ACTG 175: new insights into treating patients with intermediate-stage HIV disease.
    Folkers G.
    NIAID AIDS Agenda; 1995 Dec 01; ():4-5. PubMed ID: 11363352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.